Objection: Marketing authorisation amendment for Comirnaty (COVID-19 vaccine)

This procedure concerns a formal objection to a European Commission decision that modifies the marketing authorization for the Comirnaty COVID-19 mRNA vaccine. It focuses on ensuring that the legal and technical requirements for the vaccine's distribution and use within the EU are correctly implemented.

This primarily affects the pharmaceutical manufacturer and health regulatory bodies. It ensures that the vaccine's authorization remains compliant with EU safety and quality standards.